Bard Associates Inc Eye Point Pharmaceuticals, Inc. Transaction History

Bard Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$5.71 - $24.13 $25,695 - $108,585	-4,500 Reduced 23.56%	14,600 $337,000
Q3 2023 Nov 13, 2023	SELL	$7.99 - $15.36 $92,476 - $177,776	-11,574 Reduced 37.73%	19,100 $152,000
Q4 2022 Feb 10, 2023	SELL	$2.37 - $7.2 $5,569 - $16,920	-2,350 Reduced 7.12%	30,674 $107,000
Q2 2022 Aug 11, 2022	BUY	$7.25 - $12.71 $59,957 - $105,111	8,270 Added 33.41%	33,024 $260,000
Q3 2021 Nov 12, 2021	BUY	$7.51 - $11.72 $13,142 - $20,510	1,750 Added 7.61%	24,754 $258,000
Q2 2021 Aug 12, 2021	BUY	$8.69 - $11.08 $199,904 - $254,884	23,004 New	23,004 $207,000

163

58.2M

224K

1.41M

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $272M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

Get notified when there are updates to the investment portfolio of Bard Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Bard Associates Inc with notifications on news.